Key facts
- It has raised $14.0M; the latest was Early Stage VC in Oct 2025.
- Notable investors include Fosun Health Capital, Fosun Pharma, Jenkem Technology, Shanghai Creation Investment Management.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for DSCi Lab
- ·The full record, as it builds
Funding rounds
No funding rounds for DSCi Lab are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DSCi Lab
Developer of drug delivery systems and mRNA therapeutics focused on critical clinical needs in nucleic acid drug innovation. The company designs lipid nanoparticle platforms and ionizable lipid compounds, enabling rapid advancement of mRNA-based therapies with ongoing clinical studies and preparation for regulatory filings.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2022
- Website
- dscilaboratory.com/
- Ownership
- Privately Held (backing)
DSCi Lab doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DSCi Lab shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DSCi Lab in its N-PORT filings yet. We sweep new filings monthly.